Tg Therapeutics (TGTX) Short term Debt (2020 - 2021)
Tg Therapeutics (TGTX) posted quarterly Short term Debt of $975000.0 for Q4 2021, down 95.6% year-over-year from $22.2 million in Q4 2020, and down 93.91% quarter-over-quarter from $16.0 million in Q3 2021.
Tg Therapeutics (TGTX) Short term Debt (2020 - 2021) Analysis & Trends
Tg Therapeutics' Short term Debt history runs 2 years deep, the most recent figure standing at $975000.0 for Q4 2021.
- In Q4 2021, Short term Debt fell 95.6% year-over-year to $975000.0; the TTM figure through Dec 2021 stood at $975000.0 (down 95.6% YoY), while the FY2021 annual figure was $975000.0, down 95.6% from the prior year.
- Short term Debt for Q4 2021 stood at $975000.0, down from $16.0 million in the prior quarter.
- The five-year high for Short term Debt was $30.1 million in Q1 2021, with the low at $975000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 975,000.00 |
| Sep 30, 2021 | 16.00 Mn |
| Jun 30, 2021 | 23.16 Mn |
| Mar 31, 2021 | 30.13 Mn |
| Dec 31, 2020 | 22.18 Mn |
| Sep 30, 2020 | 14.59 Mn |
| Jun 30, 2020 | 7.20 Mn |